ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
Volume 579, Issues 1-2, 11 November 2005, Pages 182-188
Inflammation, cellular and redox signalling mechanismsin cancer and degenerative diseases
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (133 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
Special issue
View Record in Scopus
 
doi:10.1016/j.mrfmmm.2005.03.028    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2005 Elsevier B.V. All rights reserved.

Protection against paracetamol-induced hepatic injury by prazosin pre-treatment in CD-1 mice

Yuri N. ClementCorresponding Author Contact Information, E-mail The Corresponding Author and Arlene F. Williams

Pharmacology Unit, Faculty of Medical Sciences, The University of the West Indies, Trinidad and Tobago

Received 29 September 2004; 
revised 2 March 2005; 
accepted 3 March 2005. 
Available online 27 July 2005.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

A synergistic depletion of glutathione has been suggested to be one critical factor in the hepatic injury in mice induced by non-toxic doses of paracetamol (APAP) when co-administered with α-adrenergic agonists. Prazosin (an α-adrenergic antagonist) could confer hepatoprotection following a toxic APAP dose (530 mg/kg) by increasing glutathione levels and enhancing bioinactivation by glucuronidation and glutathione conjugation. The effect of prazosin pre-treatment on APAP-induced gluthathione depletion and bioinactivation in vivo was assessed. Prazosin (15 mg/kg) pre-treatment provided protection against APAP-induced hepatic injury as evidenced by a significant decrease in serum transaminase (ALT) levels after 5 h (p < 0.05). Interestingly, prazosin pre-treatment did not prevent the dramatic depletion of glutathione by high dose APAP and it had no effect on the quantity of the glutathione conjugate formed. However, prazosin pre-treatment caused a significant increase in recovery of the administered dose (530 mg/kg) as the glucuronide metabolite (p < 0.05). UDP-glucuronosyltransferase (UGT) is involved in the bioinactivation of APAP by glucuronidation and we showed that prazosin had no effect on microsomal UGT kinetics. Thus, prazosin had no effect on either APAP-mediated glutathione depletion or the extent of APAP-glutathione conjugate formation and may be affecting other mechanisms to reduce oxidative stress caused by a toxic dose of APAP.

Keywords: Paracetamol; Prazosin; Glutathione; Glucuronidation

Article Outline

1. Introduction
2. Materials and methods
2.1. Animal dosing regimen (effect of prazosin pre-treatment on paracetamol toxicity)
2.2. Determination of serum alanine transaminase (ALT)
2.3. Determination of hepatic glutathione levels
2.4. Determination of the effect of prazosin pre-treatment on hepatic paracetamol glucuronide and glutathione conjugate at low and high dose
2.5. Microsome preparation and UDP-glucuronosyltransferase (UGT) kinetic studies
2.6. Statistical analysis
3. Results
3.1. Effect of prazosin pre-treatment on serum ALT and hepatic GSH with high dose paracetamol
3.2. Prazosin pre-treatment on hepatic paracetamol metabolism and UGT kinetics
4. Discussion
Acknowledgements
References



Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
Volume 579, Issues 1-2, 11 November 2005, Pages 182-188
Inflammation, cellular and redox signalling mechanismsin cancer and degenerative diseases
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.